Table 1.
Therapeutic approaches to treat respiratory syncytial virus (RSV) infection (Source Clinical trials.gov)
| Name | Mechanism | Remarks |
|---|---|---|
| Ribavirin | Inhibition of RSV replication | High toxicity |
| Difficult administration | ||
| FDA approved | ||
| RSV604 | Inhibition of RSV replication | Safety, Tolerability and Pharmacokinetic |
| Study in Healthy Subjects complete | ||
| Phase I, complete; Phase II, in progress | ||
| 17-DMAG | Inhibition of the heat-shock protein hsp 90 | Impairs the RSV replication |
| Antitumoral drug | ||
| No clinical trial | ||
| HR121 and HR212 | Fusion inhibitor peptides | IC50 of 4·13 and 0·95 μm, respectively |
| No clinical trial | ||
| JNJ2408068 and BMS-433771 | Chemical compounds that prevent the fusion process | Phase I/II, discontinued |
| RFI-641 | Blocks viral F protein-mediated fusion and cell syncytium formation | Anti-RSV agent with potent in vitro and in vivo activity |
| Phase I/II, discontinued | ||
| ALN-RSV01 | Small interfering RNA specific against NS1 | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected with Respiratory Syncytial Virus complete |